Navigation Links
Video: CREON(R) (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines
Date:5/1/2009

- Therapy is medically-necessary for thousands of patients with exocrine pancreatic insufficiency due to cystic fibrosis or other conditions -

MARIETTA, Ga., May 1 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved CREON(R) (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. CREON(R) is the first and only pancreatic enzyme product (PEP) to receive FDA approval under new guidelines for the class.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/solvay/37345/

"Left untreated, EPI causes maldigestion, malabsorption and malnutrition and can ultimately be life-threatening," said Virginia Stallings, M.D., Director, Nutrition Center at the Children's Hospital of Philadelphia, PA and Professor of Pediatrics, University of Pennsylvania School of Medicine. "The goals of treating EPI are to optimize digestion and absorption of food and nutrients, improve outcomes for patients and prevent malnutrition and growth faltering in children and weight loss in adults. Pancreatic enzymes serve as an important component in the effective management of EPI throughout a patient's lifetime."

The efficacy of FDA-approved CREON(R) was demonstrated in a randomized, double-blind, placebo-controlled crossover study which enrolled 32 patients with CF. The primary efficacy endpoint was the coefficient of fat absorption (CFA), which measures the percentage of fat absorption relative to dietary fat intake. CREON(R) produced significantly greater mean CFA values compared to placebo in this study. The mean CFA during treatment with CREON(R) was 89% versus 49% during treatment wi
'/>"/>

SOURCE Solvay Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
2. Video: CVS Caremark Charitable Trust Awards $4.2 Million in Grants Benefiting Children with Disabilities, Uninsured
3. Video: Genworth Financial Reveals Best Places in America for Long Term Care
4. Video: Turning Hope Into Reality - Vision Research at the VA
5. Video: Turning Hope Into Reality - Traumatic Brain Injury Research at the VA
6. Video: Turning Hope Into Reality - Genomics Research at the VA
7. Video: Waters Highlights Impact of ACQUITY UPLC with Peer-to-Peer Scientist Testimonials
8. Video: Jennifer Lopez Joins the Fight Against Pertussis in New PSAs
9. Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure
10. Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality
11. Video: Adults Facing ADHD: ADHD Allies(TM) Offers Unique Online Community for Adults with ADHD on New Facebook(R) Page
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... 2014 A study published in the scientific journal ... Robert Bonin, two researchers at Universit Laval, reveals that ... new method that involves rekindling pain so that it ... novel means to alleviate chronic pain. , The researchers ... Institut universitaire en sant mentale de Qubec (IUSMQ) were ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... , MILFORD, Mass., Sept. 1 ... the Analytical Chemistry Division of the American Chemical Society presented ... Findeis Award for Achievements by a Young Analytical Scientist. Through ... Engen has pioneered the combined use of hydrogen-deuterium ...
... SAN ANTONIO, Sept. 1 Mission Pharmacal ... a one-of-a-kind formulation that provides fast, effective relief from the ... Esrubar, L.P., and formerly distributed by Beta Dermaceuticals, Inc. ... Mission Pharmacal,s strategy to accelerate growth by continuing to expand ...
... , PLANO, Texas, Sept. 1 American Institute for ... metro-Dallas area, is using Artefill to help patients fight wrinkles for ... only FDA-approved microsphere-enhanced collagen filler for the correction of smile lines ... Raphael and Dr. Scott Harris have been using to treat patients ...
... , , SCHAUMBURG, Ill., Sept. 1 ... Veterinary Medical Association (AVMA) reveal an economic mixed bag when it ... , The survey results appear in the Journal ... 2009, article entitled, "Employment, starting salaries, and educational indebtedness of year-2009 ...
... , SAN DIEGO, Sept. 1 Volcano Corporation (Nasdaq: ... products for the diagnosis and treatment of coronary and peripheral artery disease, ... Healthcare Conference 2009 on Wednesday, September 9. , , ... a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). , , ...
... , , , ... showed that in patients treated with LIVALO (pitavastatin), high-density ... patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results ... have comparable efficacy to atorvastatin and simvastatin, as measured ...
Cached Medicine News:Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 2Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 3Health News:Mission Pharmacal Acquires Dr. Smith's Diaper Ointment 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 3Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 2Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 3Health News:Volcano Corporation Presentation at Weisel Conference to be Webcast 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 3Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 4Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 5
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: